雙成藥業(002693.SZ):將注射用紫杉醇(白蛋白結合型)在美國的獨家經銷權許可授予Meitheal和HKF
格隆匯9月25日丨雙成藥業(002693.SZ)公佈,公司於2022年9月25日召開第四屆董事會第三十次會議,會議審議通過了《關於公司簽署<許可及供應協議>的議案》,同意公司與Meitheal Pharmaceuticals, Inc. (“Meitheal”)和Hong Kong King-Friend Industrial Co., Ltd.(“HKF”)簽署《許可及供應協議》。協議約定公司將研發和生產的製劑注射用紫杉醇(白蛋白結合型)(100mg/瓶)在美國地區內的獨家許可授予Meitheal和HKF。Meitheal負責注射用紫杉醇(白蛋白結合型)在美國地區內的市場規劃及銷售,產品上市後,Meitheal應向公司支付美國地區內產品銷售產生的利潤分成。HKF需向公司支付一定的一次性里程碑款項,總額為600萬美元。
注射用紫杉醇(白蛋白結合型)是一種由白蛋白包裹紫杉醇形成的納米微粒製劑,原研藥商品名:凱素(Abraxane)。經白蛋白包裹製成納米微粒後,比其它紫杉醇藥品相比注射用紫杉醇(白蛋白結合型)細胞毒性副作用顯著降低,劑量增大,抗腫瘤作用增強。此外,注射用紫杉醇(白蛋白結合型)可在腫瘤中產生積蓄,定向釋放至腫瘤細胞,具有靶向性,進一步提高藥物的療效。
此次公司將注射用紫杉醇(白蛋白結合型)在美國的獨家經銷權許可授予Meitheal和HKF,能夠快速打開注射用紫杉醇(白蛋白結合型)在美國的市場,提高注射用紫杉醇(白蛋白結合型)在美國市場的影響力和市場佔有率。本次協議的簽署對公司目前經營成果沒有重大影響,如未來在美國獲批上市,將對公司業績產生積極影響,公司將按照《企業會計準則》的相關規定進行會計處理,最終數據以公司審計機構的審計結果為準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.